Critical Appraisal of Amyloid Lowering Agents in AD.

Current Neurology and Neuroscience Reports
Boris DecourtMarwan Sabbagh

Abstract

According to the amyloid cascade hypothesis, removing amyloid beta (Aβ) should cure Alzheimer's disease (AD). In the past three decades, many agents have been tested to try to lower Aβ production, prevent Aβ aggregation, and dissolve Aβ deposits. However, the paucity in definitive preventative or curative properties of these agents in clinical trials has resulted in more avant-garde approaches to therapeutic investigations. Immunotherapy has become an area of focus for research on disease-modifying therapies for neurodegenerative diseases. In this review, we highlight the current clinical development landscape of monoclonal antibody (mAb) therapies that target Aβ plaque formation and removal in AD. Multiple potential disease-modifying therapeutics for AD are in active development. Targeting Aβ with mAbs has the potential to treat various stages of AD: prodromal, prodromal to mild, mild, and mild to moderate. Monoclonal antibodies discussed here include aducanumab, lecanemab, solanezumab, crenezumab, donanemab, and gantenerumab. The final decision by the FDA regarding the approval of aducanumab will offer valuable insight into the trajectory of drug development for mAbs in AD and other neurodegenerative diseases. Future directio...Continue Reading

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B DeMattosD M Holtzman
Dec 31, 2003·Journal of Molecular Biology·Justin LegleiterTomasz Kowalewski
Jan 14, 2004·Neurology·S A ReinesUNKNOWN Rofecoxib Protocol 091 Study Group
Nov 23, 2005·PLoS Biology·Douglas M FowlerJeffery W Kelly
Mar 10, 2006·Science of Aging Knowledge Environment : SAGE KE·Dietmar R ThalHeiko Braak
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashley I Bush, Rudolph E Tanzi
Dec 2, 2008·Neurochemistry International·Saravanan S KaruppagounderGary E Gibson
Mar 11, 2009·Frontiers in Bioscience (Landmark Edition)·Seth LovePatrick Kehoe
Dec 17, 2009·JAMA : the Journal of the American Medical Association·Robert C GreenUNKNOWN Tarenflurbil Phase 3 Study Group
Feb 17, 2010·Nature Reviews. Neurology·Kaj BlennowHenrik Zetterberg
Jul 5, 2011·Nature Neuroscience·Takashi SaitoTakaomi C Saido
Jan 10, 2012·Cold Spring Harbor Perspectives in Medicine·Alberto Serrano-PozoBradley T Hyman
Jan 31, 2012·Nature Neuroscience·Iryna BenilovaBart De Strooper
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Darin JaturapatpornNaji Tabet
Jul 13, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Oskar AdolfssonRyan J Watts
Mar 26, 2013·International Journal of Geriatric Psychiatry·Stephen ToddA Peter Passmore
Jan 24, 2014·The New England Journal of Medicine·Rachelle S DoodyUNKNOWN Solanezumab Study Group
Feb 8, 2014·Nature Medicine·Jing L Guo, Virginia M Y Lee
Feb 25, 2014·The Cochrane Database of Systematic Reviews·Elizabeth L SampsonRupert McShane
Aug 22, 2014·The Biochemical Journal·Katelyn M SeitherJames Shorter
Dec 24, 2014·Acta Neuropathologica·Dietmar Rudolf ThalMarcus Fändrich
Apr 12, 2015·Acta Neuropathologica·Sylvie BurnoufLinda Partridge
Sep 29, 2015·JAMA Neurology·Vladimir CoricRobert M Berman
Mar 24, 2016·Journal of Medicinal Chemistry·Matthew G BursavichJean-François Blain
Aug 6, 2016·Current Diabetes Reports·Lindsay A ZillioxJames W Russell
Sep 2, 2016·Nature·Jeff SevignyAlfred Sandrock
Nov 5, 2016·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ksenia V KastanenkaBrian J Bacskai
Dec 21, 2016·Scientific Reports·Mark UltschWeiru Wang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

DIAN
EMERGE
ClarityAD
PRIME
BLAZE
TU
ExpeditionPRO
ENGAGE

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.